Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for December 2010
December 1, 2010
- Shire Reports Positive Efficacy and Safety Results From FAST-3 Study of FIRAZYR (icatibant) for Acute Attacks of Hereditary Angioedema
- Data Published in Current Opinion in Lipidology Suggest Anti-Inflammatory Role for Oxidized Phospholipid Analogs, including VB-201, Lead VBL Compound
- Allos Therapeutics Announces FOLOTYN Data to Be Presented as a Late Breaker at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology
- Oramed Pharmaceuticals Announces Publication in the Journal of Diabetes Science and Technology
- Encouraging Data on Astex?s Anti-Cancer Drug AT9283 to be Presented at ASH
- Drug Regarded as Alternative to Standard Treatment for Preventing Relapse of Certain Type of Vasculitis Does Not Appear as Effective
- 52nd ASH Annual Meeting Presentation of Initial Phase II Data from the Saphire Hodgkin's Lymphoma Trial with Resminostat
- Data at ASH, SABCS demonstrate commitment of Novartis R&D in advancing treatments for patients with cancer and rare diseases
- Pixantrone Phase III End of Study Results to be Presented at the 52nd Annual Meeting of the American Society of Hematology
- Sierra Sciences' Plan to Cure Aging is Validated by Newly Published Proof of Concept Experiment
- Observational Data From One-Year Follow-up Study Validate Six-Minute Walk Distance as an Outcome Measure in Duchenne and Becker Muscular Dystrophy
- Stemline Therapeutics, Inc. Announces Presentations of SL-401 Clinical and Pre-Clinical Efficacy at the 52nd Annual Meeting of the American Society of Hematology (ASH)
- Molecular Mechanisms That Could Explain Unique Adverse Events Observed in Patients Treated With the Antibiotic Telithromycin (Ketek) is Reported in Antimicrobial Agents and Chemotherapy
- Small Australian Research Team Yields Big Results Towards Finding a Cure for Chagas Disease
December 2, 2010
- New Clinical Data Evaluating AVEO's Tivozanib in Combination with Paclitaxel to be Presented at 33rd Annual San Antonio Breast Cancer Symposium
- Aeterna Zentaris Announces Poster Presentations of Perifosine at the Upcoming 52nd Annual Meeting of the American Society of Hematology
- Keryx Biopharmaceuticals Announces Poster Presentations of KRX-0401 (Perifosine) at the 52nd Annual Meeting of the American Society of Hematology
- New Gene for Childhood Cancer Neuroblastoma Is Discovered
- Trillium's Cancer Stem Cell Program to be Highlighted at ASH
- Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
December 3, 2010
- Dendreon Announces Presentation of PROVENGE Data at the American Society of Hematology and the Society of Urologic Oncology Annual Meetings
- Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinson's Disease
- Gene Duplication Detected in Depression
- Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting
- Blood Vessel Dysfunction Linked to Heart Disease Also Impacts Alzheimer's
- Researchers Achieve Extensive Regeneration in Nerve Connecting Eye to Brain
- US Oncology Research Investigators Participated in Studies That Will be Presented at the 2010 American Society of Hematology Annual Meeting and Exposition
December 6, 2010
- Telik Announces Final Positive Phase 2 Results of a Multicenter Study of Oral Ezatiostat Hydrochloride (TELINTRA, TLK199) in Patients with Myelodysplastic Syndrome
- PROCHIEVE 8% Vaginal Progesterone Gel Achieves Primary Endpoint in Phase III Study to Reduce Risk of Preterm Birth
- YM BioSciences Notice of Analyst Meeting and Conference Call
- Longer-term Phase III Data Show Novartis Drug Tasigna Continues to Surpass Gleevec in Slowing Disease Progression in Patients with Newly Diagnosed CML
- XIAFLEX Effective in Nonsurgically Treating MP and PIP Joints with Dupuytren's Contractures in Second Pivotal Study
- Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting
- Promising Data Presented on GenVec RSV Program
- Aeterna Zentaris: Phase 2 Data Demonstrate Perifosine's Promising Efficacy in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
- Cinryze (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
- Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia
- Generex Presents New Positive AE37 Phase II Breast Cancer Vaccine Data
- S*BIO's Novel JAK2 Inhibitor SB1518 is Shown to Be a Safe and Effective Therapy in Phase 1/2 Studies For Patients with Symptomatic Myelofibrosis and Relapsed/Refractory Lymphoma
- YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
- Novartis Phase II LBH589 Data Show Substantial Disease Control and Tumor Reduction in Extensively Pretreated Hodgkin Lymphoma Patients
- China Pharma Holdings, Inc. Announces Successful Completion of Clinical Trials of the Cholesterol-Lowering Drug, Rosuvastatin
- Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate
- Spherix to Hold Business Update Conference Call December 9, 2010 at 4:30 p.m. Eastern Time
- Biovest Reports a Significant Discovery in Cancer Vaccines for Lymphoma: Vaccine Isotype Determines Improvement in Disease-Free Survival Following Vaccine Therapy
- Follow-Up Results from Study Comparing SPRYCEL (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data
- New Studies Support Therapeutic Potential of Compugen Discovered Target for Multiple Myeloma Treatment
- Micromet's Blinatumomab Produces High Objective Response Rate in Spectrum of Relapsed Non-Hodgkin's Lymphoma Patients
December 7, 2010
- Celator Pharmaceuticals Presents Positive Data from Phase 2 Study of CPX-351 at the American Society of Hematology Annual Meeting
- Encouraging Phase 2 Interim Data for Elotuzumab in Relapsed Multiple Myeloma Presented at 52nd American Society of Hematology Annual Meeting
- Better Treatment Adherence and Lower Health Costs for Cancer Patients Using nilotinib
- CytRx's INNO-206 Safely Delivers High-Dose Doxorubicin to Human Tumors in Animal Model of Multiple Myeloma
- Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
- Presentation at American Society of Hematology Annual Meeting Confirms Inhibiting Unfolded Protein Response is Promising Treatment for Multiple Myeloma
- Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study
- ZEVALIN Data as Preparatory Regimen Presented Prior to Autologous and Allogeneic Stem Cell Transplantation in the Treatment of Non-Hodgkin's Lymphoma
- Achillion to Present Data From Studies of ACH-1625 in Hepatitis C at Asian Pacific Liver Conference
- Velcade (bortezomib) administered subcutaneously shows comparable response rates and safety profile compared to intravenous administration in the treatment of relapsed multiple myeloma
- Long-term Use of Antiepileptic Drug Vimpat (Lacosamide) C-V Effectively Reduced Partial-Onset Seizure Frequency and Improved Health-related Quality of Life
- Researchers Offer New Hope for Stroke Patients
- New Pixantrone Data Presented at Meetings at American Society of Hematology Conference
- Virginia Tech engineer identifies new concerns for antibiotic resistance, pollution
- Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B
- Discovery Labs Aerosurf Improves Lung Function and Reduces Inflammation in a Dose-Dependent Fashion in Established Non-Clinical Model of Preterm Respiratory Distress Syndrome
- Ascenta Therapeutics and The Leukemia & Lymphoma Society Announce Agreement to Develop AT-406 for Leukemia
- Aduro BioTech's Clinical Results from CRS-207 Phase 1 Trial Presented at AACR Special Conference
- Baxter Presents Interim Phase 1 Safety and Tolerability Data at American Society of Hematology Meeting for Its Investigational Treatment for von Willebrand Disease
- ChemGenex Presents Updated Analysis at ASH on OMAPRO in CML Patients who Failed Two or Three Approved TKI Drugs
December 8, 2010
- Keryx (KERX): Promising Phase 2 At ASH For Three Cancers
- Phase I Trial Indicates Ponatinib May Thwart Most Resistant CML
- Kyowa Hakko Kirin Announces Results from US Phase 1/2 Clinical Trial of KW-0761 (Anti-CCR4 Humanized Monoclonal Antibody) in Patients with Cutaneous T-cell lymphoma
- Lundbeck reports positive phase III study results for clobazam in the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome
- Clinical Data, Inc. Announces Vilazodone Data Presented at American Society of Health System Pharmacists
- Medivir's U.S. commercialisation partner Meda presents positive Xerese data at ASHP
- MolMed presents new data for its cell based therapy TK at the Annual Meeting of the American Society of Hematology (ASH)
- Rexahn Pharmaceuticals Presents Serdaxin Phase IIa Clinical Data at the American College of Neuropsychopharmacologists Annual Meeting
- Octapharma Researchers Propose New Objective Criteria for Evaluating the Treatment of von Willebrand Disease
- Alkermes Announces Results from Phase 2 Study of ALKS 33 in Alcohol Dependence
- Edoxaban Demonstrates Superior Efficacy Compared With Enoxaparin Sodium in Preventing VTE After Total Hip Replacement
- Dynavax Reports Phase 1a Safety and Immunogenicity Results for Universal Flu Vaccine
December 9, 2010
- Protox Announces Publication of Prx302 Clinical Data for Benign Prostatic Hyperplasia in European Urology
- Tengion Announces New Kidney Data at TERMIS
- Universal Flu Vaccine Shows Positive Results
- Cytheris Announces Interim Results of Phase I Study Showing That Recombinant Human Interleukin-7 (CYT107) Promotes T-Cell Recovery Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
- Pro-Pharmaceuticals Expands Patent Coverage to Australia
- PolyMedix Presents PMX-60056 Clinical Data at American Society of Hematology Meeting
- Novelos Therapeutics Announces Presentation of Positive Phase 2 Results in NOV-002 Neoadjuvant Breast Cancer Trial at San Antonio Breast Cancer Symposium
- Spherix Phase 2 Trial with D-tagatose Determines Minimum Dose for HbA1c and Triglycerides
- Teva Announces Successful Results of Phase III Study with Oral Laquinimod For Multiple Sclerosis
- Aromatase Inhibitors Increased Risk of Heart Disease in Postmenopausal Women With Breast Cancer
- Drug Combination Shows Promise for Newly Diagnosed Blood Cancer Patients, Study Finds
- Memgen Announces Clinical and Preclinical Results for ISF35 in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
- Sanofi-aventis Oncology Data to be Presented at San Antonio Breast Cancer Symposium
- Neovacs Reports Successful Results of Immunotherapy Trial for Crohn's Disease Patients
- New Data Confirm Naurex's Novel Antidepressant is Free of Ketamine-Like Effects
- Esophageal Cancer Risk Lower Than Expected for Patients with Acid Reflux Disease
- Study Shows Novartis Drug Afinitor Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
- Data for ENMD-2076 Phase 1 Studies in Multiple Myeloma and Leukemia Presented at ASH
- Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
- S*BIO's Oral Histone Deacetylase (HDAC) Inhibitor SB939 Shows Tolerability and Safety in Phase 1 Clinical Trial in Patients with Advanced Hematologic Malignancies
- XIAFLEX CORD II Study Published in The Journal of Hand Surgery
- Subcutaneous Administration of Single-Agent VELCADE Demonstrates Efficacy Consistent with Intravenous Administration
- Weekly VELCADE in Combination with Rituximab Improves Progression-Free Survival and Response Rate in Patients with Relapsed or Refractory Follicular Lymphoma
December 10, 2010
- Latuda (lurasidone HCl) Significantly Improves Symptoms of Schizophrenia in Fifth Positive Placebo-Controlled Study
- Buprenorphine Treatment in Pregnancy: Less Distress to Babies
- EpiCept Reports New Analysis Supports Ceplene's Favorable Impact on Overall Survival
- AVEO's Tivozanib in Combination with Paclitaxel Demonstrates Safety in Patients with Metastatic Breast Cancer; Data Presented at San Antonio Breast Cancer Symposium
- Study of Novartis Drug Zometa for Potential New Use in Early Breast Cancer Did Not Meet Primary Endpoint in Overall Study Population
- Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor Disappearance in Study of Women With Newly Diagnosed, Early-Stage HER2-Positive Breast Cancer
- VELCADE Induction Followed by VELCADE Maintenance Improves Clinical Outcomes in Previously Untreated Multiple Myeloma Patients
- New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations
- Phase 2 Clinical Data on NKTR-102 in Metastatic Breast Cancer to Be Presented at 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium
- Euthymics Bioscience, Inc. Presents Phase II Data for EB-1010 in Major Depression at ACNP Annual Meeting
- Excellent Safety and Reproducible Immunogenocity Demonstrated in Early Results of Phase 2a Trial for Hiv Preventative Vaccine
- Drugs are Safe, Active in Patients Normally Ineligible for Clinical Trial
- Immune system changes linked to inflammatory bowel disease revealed
- New Analysis from Phase 2b Study Reinforces Favorable Survival Data Observed with FOLOTYN® Relative to Erlotinib in Advanced Non-Small Cell Lung Cancer
December 13, 2010
- Generex Announces Publication of New Positive Generex Oral-lyn Data in Peer-Reviewed Journal
- GTx Presents Results of the Capesaris (GTx-758) Phase II Proof of Concept Pharmacokinetic-Pharmacodynamic Clinical Trial
- Sangamo BioSciences Announces Publication of Data From Program to Develop a ZFP Therapeutic for Parkinson's Disease
- Cytokinetics Announces Successful Completion of Phase IIA ?Evidence of Effect? Clinical Trial of CK-2017357 in Patients with Amyotrophic Lateral Sclerosis
- Intercell Provides Update on Clinical Trials for the Patch-Based Travelers' Diarrhea Vaccine
- Amgen Presents New Xgeva (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
- Chimerix's Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
- PharmaNet's Technology Investments Translate to Enhanced Client Service in Its Phase I Clinics
- Depression Drug May Relieve Pain From Breast Cancer Treatment, U-M Study Finds
- Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer
- IMGN: T-DM1 Data Presented at San Antonio Breast Cancer Symposium
- GTx?s Prostate Compound Reaches Endpoints in Phase II Proof of Concept Study
- ImmunoGen, Inc. Announces Clinical Data for T-DM1 Used in Combination with Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
- More Node Negative Patients Surviving Breast Cancer: Findings Reported at 2010 San Antonio Breast Cancer Symposium
- Study Shows How Flu Infections May Prevent Asthma
- NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
December 14, 2010
- Profectus Biosciences' GENEVAX IL-12 Adjuvant Significantly Improves pDNA Vaccine Performance in Phase I Human Trial
- Compugen Announces Positive Therapeutic Effect of CGEN-15001 in Animal Model of Rheumatoid Arthritis
- Agios Announces Cancer Cell Publication of Research Illuminating Link between Cancer Metabolism and Epigenetics
- Amira Pharmaceuticals to Present Preclinical, Clinical Data from DP2 Receptor Antagonist Program at Pacifichem 2010
- Inhibitex Reports Promising Top-Line Results from Phase II Trial of FV-100 for the Treatment of Shingles
- Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
- Vical's Vaxfectin Demonstrates Potential as "Universal" Adjuvant
- RFS Pharma's New dioxolane nucleoside Prodrugs have Potent and Selective anti-HIV Activity
December 15, 2010
- Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
- 2009 H1N1 Vaccine Safe and Induces Robust Immune Response in People With Asthma
- Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy
- Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Atopic Dermatitis
- Generex Announces Publication of New Positive Generex Announces Publication of New Positive Generex Announces Publication of New Positive Generex Oral-Lyn Data in Peer-Reviewed Journal
December 16, 2010
- Alnylam Presents New Data on Delivery of RNAi Therapeutics and Human Translation
- Adeona Acquires Access to Clinical Data Supporting Oral Zinc for Prevention of Infections in the Elderly
- CHOP Experts Collaborate in Gene Survey of Childhood Brain Cancer; Intriguing Clues Found
December 17, 2010
- An ITG Majestic Market Research Study Indicates a Bright Future for Gilenya, Despite Concerns About Its Safety
- Heart Disease, Stroke Deaths Continue to Fall But Costs Remain High
- Viron Phase 2A Data Published in Leading Cardiovascular Journal, Circulation: Cardiovascular Interventions
- TIGER-1 Denufosol Phase 3 Trial for Cystic Fibrosis Published in the American Journal of Respiratory and Critical Care Medicine
December 20, 2010
- Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
- Idera Pharmaceuticals Announces Preliminary Data from Phase 1 Clinical Trial of IMO-2125 in Treatment-Naïve Genotype 1 HCV Patients
- Biovest Issues Post-ASH Update for BiovaxID Personalized Cancer Vaccine including Significance of Isotype Phase III Data
- Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
- Genzyme Details Market Potential of Alemtuzumab for MS
December 21, 2010
- NanoViricides Announces That The Company Has Been Invited To Present at Dengue Research Meeting Sponsored by the National Institutes of Health
- Amorcyte Stem Cell Therapy Demonstrates Clinically Significant Reperfusion in Severe Heart Attack Patients
- Gold Nanomedicine Clinical Trial Delivers Promising Results
- EHSI: New Stem Cell Treatment Could Help Cure Diabetes
- ReNeuron gives update on progress of stroke stem cell clinical trial
- Novartis investigational JAK inhibitor INC424 data met primary endpoint in Phase III trial of patients with myelofibrosis
- Incyte Announces Positive Top-Line Results from COMFORT-I Pivotal Phase III Trial of INCB18424 in Myelofibrosis, a Debilitating, Life-Threatening Blood Cancer
- Strict Heart Rate Control Provides No Advantage Over Lenient Approach
December 22, 2010
- NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate
- American Heart Association/American Stroke Association 2010 Top Ten Research Reports
- Acino confirms the potential of iclaprim as a new antibiotic
- Oxford Biomedica Announces Update on Prosavin Phase I/II Study in Parkinson?s Disease
December 23, 2010
- Newly Published Investigational Apixaban ADVANCE-3 Study Results Demonstrate Statistical Superiority to Enoxaparin with Comparable Rates of Bleeding in the Prevention of Venous Thromboembolism Following Total Hip Replacement Surgery
- Repros Therapeutics Submits Data to the FDA Supporting Morning Assessment of Testosterone for Men Treated with Androxal as Indicative of Average and Maximum Levels Attained
- Degludec significantly reduces risk of hypoglycaemia during the night compared to insulin glargine in two long-term studies
December 28, 2010
- Vaginal Delivery of Repros? Proellex Bypasses First Pass Liver Effects and Achieves Greater Signals of Efficacy at Significantly Lower Exposure
- Tivorsan Pharmaceuticals? Biglycan Protein Opens Unique Path for Preserving Muscle Function in Duchenne Muscular Dystrophy
- Dynavax Reports Phase 1B Safety and Immunogenicity Results for Hepatitis B Therapy Candidate
- Reanalysis by Outside Statistician Shows Androxal Provides Statistically Significant Improvement in Testosterone Levels in Men with Male Hormone Levels ? 250 ng/dL
December 29, 2010
- Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
- Cardiome Provides Update for Oral Vernakalant Development Program
- Poor Response to Anti-Anemia Drug Predicts Higher Risk of Heart Disease Or Death
